2018
DOI: 10.1159/000493684
|View full text |Cite
|
Sign up to set email alerts
|

The Effect of Recombinant Human Erythropoietin on Bacterial Growth: A Dual-Edged Sword

Abstract: Background: Hypererythropoietinemia is associated with common diseases like non-uremic anaemia where infection burden is high. Erythropoietin (EPO) is also given as therapy for anaemia associated with chronic kidney disease and cancer and in those who are at a higher risk of infections. EPO is known to have an effect on macrophages by which it helps in the growth of some intracellular pathogens. However, its direct role on bacterial growth is currently unknown. Summary: Here, we investigated the direct effect … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 28 publications
0
3
0
Order By: Relevance
“…In vitro, the level of E. coli was elevated after the application of rhuEPO. Thus, the upregulation of E. coli after roxadustat treatment maybe a result of the promotion of EPO [ 66 ]. The function of E. coli in ESRD patients is an unsettled question and need further study.…”
Section: Discussionmentioning
confidence: 99%
“…In vitro, the level of E. coli was elevated after the application of rhuEPO. Thus, the upregulation of E. coli after roxadustat treatment maybe a result of the promotion of EPO [ 66 ]. The function of E. coli in ESRD patients is an unsettled question and need further study.…”
Section: Discussionmentioning
confidence: 99%
“…The downloaded of rHuEPO-alpha structure by protein data bank, has been used code of rHuEPO- alpha structure which are (1EER) [11]. A molecular docking of rHuEPO-alpha with MgO NPs was performed by Molecular Graphics Laboratory (MGL) with used auto dock with version 1.5.6.…”
Section: Docking Studymentioning
confidence: 99%
“… 82 , 95 Patients in the low-dose arm also required significantly higher ESA doses, and recent data suggest that erythropoietin can enhance the growth of some bacteria (eg, E coli and S aureus ). 108 Although PIVOTAL has added greatly to the evidence base, several unanswered questions remain. For instance, it remains uncertain whether the infection-related results of the PIVOTAL trial can be generalized to: (1) non–dialysis-dependent CKD populations, (2) patients receiving peritoneal dialysis, (3) prevalent HD populations, (4) other iron formulations, (5) patients with ferritin levels > 700 μg/L, (6) patients not receiving ESAs, or (7) patients treated with hypoxia-inducible factor prolyl hydroxylase inhibitors.…”
Section: Clinical Implications and Areas Of Uncertaintymentioning
confidence: 99%